Medicine
Lithobid 300 mg extended-release tablet
Lithobid 300 mg extended-release tablet is a prescription medicine containing Lithium carbonate for oral use, marketed by ANI Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store between 59° to 86°F (15° to 30°C). Protect from moisture.
Key facts
- Active ingredient (INN)
- Lithium carbonate
- Brand
- Lithobid
- Strength
- 300 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- ANI Pharmaceuticals
- Manufacturer
- ANI Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store between 59° to 86°F (15° to 30°C). Protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 July 2014
- Identifiers
- RxCUI 197891, 206786DailyMed set ID f7f5b69a-c2a1-4586-a189-1475d41387c0NDC 62559-280Application NDA018027
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated, extended release in 1 bottle | 62559-280-01 | ANI Pharmaceuticals | 1 July 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 6 April 1970 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lithium carbonate 300 mg extended-release tablet.
Other strengths and forms of Lithium carbonate
Clinical summary
Lithium carbonate is a mood stabilizer indicated as monotherapy for the treatment of bipolar I disorder, among other approved uses. It is available as capsules, extended-release tablets and tablets for oral use. MedsAcross supplies Lithium carbonate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Lithium carbonateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Lithium Carbonate prescribing information (Hikma Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Lithobid 300 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.